# LMY-920 for Treatment of Relapsed or Refractory Myeloma

> **NCT05546723** · PHASE1 · RECRUITING · sponsor: **Luminary Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma, Refractory
- Multiple Myeloma in Relapse

## Interventions

- **BIOLOGICAL:** Autologous CAR-T cell therapy expressing the BAFF-ligand.

## Key facts

- **NCT ID:** NCT05546723
- **Lead sponsor:** Luminary Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546723, "LMY-920 for Treatment of Relapsed or Refractory Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05546723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*